Skip to main content
. 2022 Jun 27;13:901772. doi: 10.3389/fimmu.2022.901772

Figure 1.

Figure 1

Immunotherapies based on anti-PD-1/PD-L1 pathway antibodies. (A) Inhibition of T cell activity caused by binding programmed death ligand 1 (PD-L1) to programmed death (PD-1). (B) Activization of T cell activity by using anti-PD-1 or anti-PD-L1 antibodies. The cancer cells become immunogenic again. This leads to recognition of tumor cells by T cells and final elimination by the host immune system.